PCN132 Cost-Effectiveness Analysis of RE-Treatment with 177lu-Dotatate Versus NO RE-Treatment with 177lu-Dotatate in Patients with Progressive Midgut Neuroendocrine Tumors
Dec 1, 2020, 00:00
10.1016/j.jval.2020.08.269
https://www.valueinhealthjournal.com/article/S1098-3015(20)32525-0/fulltext
Title :
PCN132 Cost-Effectiveness Analysis of RE-Treatment with 177lu-Dotatate Versus NO RE-Treatment with 177lu-Dotatate in Patients with Progressive Midgut Neuroendocrine Tumors
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(20)32525-0&doi=10.1016/j.jval.2020.08.269
First page :
Section Title :
Open access? :
No
Section Order :
10215